

THE UNIVERSITY OF TEXAS
**MD Anderson
Cancer Center**

Making Cancer History®

**R/R B-ALL PHASE 1/2 CLINICAL TRIAL
(NCT03698552)**

**ADCT-602, A Novel CD22-Targeting
PBD-Based Antibody Drug Conjugate
in R/R B-ALL**

STUDY PURPOSE

This is a phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of ADCT-602 in patients with R/R B-ALL. Phase I consists of a 3+3 dose escalation and Phase 2 follows a Simon minimax 2-stage design.

KEY INCLUSION CRITERIA

- Aged ≥18 yrs
- R/R CD22-positive B-ALL
- Marrow blast count ≥5%
- ECOG PS 0-2
- Adequate cardiac, renal and liver function

STUDY DRUG ADMINISTRATION

ADCT-602 is given IV once every 3 weeks.

STUDY SITE

The University Of Texas MD Anderson Cancer Center, Houston, TX

For more information about the study and to refer potential patients, please contact:

Dr. Nitin Jain

njain@mdanderson.org | 713-745-6080

Dr. Elias Jabbour

ejabbour@mdanderson.org | 713-792-4764

Dr. Hagop Kantarjian

hkantarjian@mdanderson.org | 713-792-7026



**Chief, Section of Hematology
Director, DeLuca Center for Innovation
in Hematology Research**

Professor

The Yale Cancer Center invite applications from board-certified/board eligible hematologists to serve as the Chief for the Section of Hematology and the Director of the DeLuca Center for Innovation in Hematology Research. The incoming Chief should have a demonstrated academic record consistent with the level of Professor at Yale School of Medicine and will be proposed as the Arthur H. and Isabel Bunker Professor of Medicine at Yale School of Medicine. In addition to being active clinically, this position has the administrative responsibility of overseeing the Section of Hematology, which includes faculty committed to myeloid, lymphoid and myeloid malignancies, stem cell transplantation and CAR-T cell therapies, and benign hematology.

The incoming physician leader will have responsibility for the clinical and academic activities of the Section, including research management, education, strategic planning, faculty recruitment and retention, faculty development/mentorship, in addition to leadership of the recently launched DeLuca Center for Innovation in Hematology Research. Of particular importance is experience building a leading extramurally funded programs in clinical, translational, or basic science research, a track record as an accomplished individual investigator, mentorship of young investigators, oversight of a growing clinical operation, facilitating an inclusive culture, and building strong cooperative teams across disciplines.

This position involves research activities, expectations for participating in the teaching mission, and a commitment to clinical medicine. Yale values diversity in its faculty, students, and staff and strongly encourages applications from women, members of minority groups, persons with disabilities, and protected veterans. Review of applications will begin immediately and continue until the position is filled.

All application materials, including CV and a letter of interest, should be submitted electronically to:

<http://apply.interfolio.com/49102>

Yale University School of Medicine is an Equal Opportunity/Affirmative Action Employer.



Faculty Position in Stem Cell Research Princess Margaret Cancer Centre at the UHN

The Princess Margaret Cancer Centre at the University Health Network (UHN) is seeking an outstanding Scientist with a research program focused on the biology and translational applications of stem cells in cancer. Expertise in genetics, epigenetics, or metabolism would be of asset.

We are seeking to recruit a PhD or MD/PhD scientist within the first years of completing their post-doctoral fellowship. The successful candidate will have an outstanding research track record during their PhD and postdoctoral training and be expected to develop an independent world-class research program.

The Princess Margaret Cancer Centre, one of the top cancer research centres worldwide, has a longstanding history of landmark discoveries in stem cell research dating back to the original identification of stem cells by Drs. Till and McCulloch. Understanding stem cell biology in cancer and normal hematopoiesis remains a core strength and priority of the centre.

The Princess Margaret Cancer Centre is a member of the University Health Network (UHN) which encompasses Toronto General Hospital, Toronto Western Hospital, Toronto Rehabilitation Institute, Michener Institute of Education and Princess Margaret Cancer Centre. Research across UHN's research institutes spans the full spectrum of diseases and disciplines, including cancer, cardiovascular sciences, transplantation, neural and sensory sciences, musculoskeletal health, rehabilitation sciences, and community and population health. The breadth of research, the complexity of the cases treated, and the magnitude of its educational enterprise has made UHN a national and international resource for patient care, research and education. With a long tradition of ground-breaking firsts and a purpose of "Transforming lives and communities through excellence in care, discovery and learning", UHN, Canada's largest research teaching hospital, bringing together over 16,000 employees, more than 1,200 physicians, 8,000+ students, and many volunteers. UHN is a caring, creative place where amazing people are amazing the world.

The successful candidate will be eligible for appointment at the Assistant Professor level in the Department of Medical Biophysics or related departments at the University of Toronto. Compensation for this position will be commensurate with experience and be consistent with UHN compensation policy (range of \$90,000 - \$180,000 plus benefit package). The full-time permanent position is available immediately, but the search will remain open until the position is filled. The position will be located in Toronto.

Interested candidates should apply below and also send their CV, as well as a description of their research interests and program to **Dr. Aaron Schimmer, Research Director, Senior Scientist, Staff Physician, Princess Margaret Cancer Centre, 610 University Avenue, Rm 7-504, Toronto, Ontario, Canada M5G 2M9; E-mail: Aaron.Schimmer@uhn.ca**

UHN is a respectful, caring, and inclusive workplace. We are committed to championing accessibility, diversity and equal opportunity. All qualified candidates are encouraged to apply.

A Comprehensive Board Review in Hematology and Medical Oncology

presented by

*The University of Texas MD Anderson Cancer Center
and
Baylor College of Medicine*

September 16-21, 2019

UT MD Anderson Cancer Center
1515 Holcombe Blvd.
Houston, TX

Websites:

www.mdanderson.org/hmobr or
www.mdanderson.org/conferences

Email: register@mdanderson.org

Phone: 713-792-2223 or 1-866-531-MOBR (6627)

Hematologist/Oncologist: Exciting opportunity to work in the new Upstate Cancer Center. The Department of Medicine at Upstate Medical University has an opening for an Assistant/ Associate Professor in their continuously expanding Division of Hematology/Oncology. This is a unique opportunity at an academic medical center with responsibilities that include clinical care, teaching, and the development and management of research studies. The Division consists of 16 faculty, 9 fellows and offers the freedom to grow in its combined Hematology/Oncology program, multi-disciplinary programs, and research activities fully supported by Research Administration and Clinical Research Associates. Candidates with an interest in Medical Directorship and Quality Management are a high priority. Academic rank and competitive salary dependent on qualifications. Excellent benefits. The beautiful Central New York Finger Lakes region offers excellent schools, affordable housing, numerous recreational and social activities and beautiful seasonal weather. MD/MBBS, BC/BE in Oncology and/or Hematology and NYS license or eligible.

Please forward CV to: Deborah J. Tuttle, SUNY Upstate Medical University, Department of Medicine, 550 East Genesee Street, Suite 201, Syracuse, NY 13202 or **email to: tuttled@upstate.edu**

Upstate Medical University is an AA/ADA/EEO employer committed to excellence through diversity. Applications from women and minorities are strongly encouraged.



Seeking Hematologists to develop a Benign Hematology Service

Dignity Health St. Joseph's Hospital and Medical Center is seeking board certified/board eligible hematologists to develop a benign hematology program to supplement our Centers of Excellence (COE). Those COEs include The University of Arizona Cancer Center at Dignity Health St. Joseph's (includes all malignancies and Cellular Therapy), the Norton Thoracic Institute (one of the busiest lung transplant programs in the country), the Liver and Kidney Transplant program, Dignity Health Medical Group Internal Medicine and Surgical Specialists, and The Barrow Neurologic Institute. Dignity Health St. Joseph's recently implemented a Destination Medicine program and is receiving calls for care from persons outside of our local service area and from Canada and other countries. Along with an inpatient consult service, an outpatient clinic, the development of an apheresis service and an anti-coagulation clinic are highly desirable. Faculty appointments to Creighton University and The University of Arizona are available for qualified candidates and many teaching and clinical trial participation opportunities are available.

We offer unique opportunities to build best-in-class patient care programs by combining the academic strengths of Creighton University and the University of Arizona Comprehensive Cancer Center (UACC) with the outstanding care provided by St. Joseph's Hospital & Medical Center, the flagship hospital of Dignity Health, and now a member of CommonSpirit Health (the largest not-for-profit health care company in the Country). The City of Phoenix is the 5th largest city in the country and one of the fastest growing since 2016. We are known for our wonderful climate and many outdoor and indoor recreational activities. The Benign Hematology team will work closely with the leadership of both Dignity Health St. Joseph's Hospital and the Malignant Hematology Program at the Cancer Center to ensure the growth of the comprehensive patient care programs as well as the implementation and growth of the translational and clinical trials programs.

For more information or to apply, please contact:

**Jennifer Laughlin, Sr. Physician Recruiter at
CancerCenterRecruiting@DignityHealth.org**



**King Endowed Professor of Cancer Research
Rush University Medical Center / Rush University Cancer Center
Chicago, Illinois**

Rush University Medical Center invites applications for **The Robert E. and Emily H. King Endowed Professor of Cancer Research** in the Department of Internal Medicine, Division of Hematology, Oncology and Cell Therapy. The ideal candidate is a physician scientist focused on **immunotherapy in the treatment of lymphoma and hematologic cancers**. The successful candidate will have a demonstrated history of extramural grant funding, an established reputation in the field and will be eligible to meet criteria as an incoming associate professor or professor. Eligible candidates will be expected to possess a MD, PhD or MD/PhD degree. The predominant criteria include: a major commitment to research and scholarly activity that advances the field of medicine, teaching, and institutional service appropriate to the programmatic need the individual is expected to fulfill.

The vision for **The Robert E. and Emily H. King Cancer Immunotherapy Research Program** is to develop the next generation of cellular and immunologic treatments for hematologic malignancies, focused initially on lymphoma, leukemia, or myeloma. To support this position, substantial annual financial support is committed for a 5-year period to fund the laboratory and translational science goals of the King Cancer Immunotherapy Research Program, above and beyond the candidate's current grant funding. Furthermore, the successful candidate is anticipated to achieve substantial productivity during this time so as to be eligible to assume an endowed professorship that will support the Endowed Professor's cancer research at Rush in perpetuity. The endowment financial support may be used for salary, laboratory staff and equipment.

Rush University System for Health (RUSH) is an academic health system whose mission is to improve the health of the individuals and the diverse communities it serves through the integration of outstanding patient care, education, research and community partnerships. RUSH comprises Rush University Medical Center, Rush University, Rush Copley Medical Center and Rush Oak Park Hospital, as well as numerous outpatient care facilities. Rush University, with more than 2,500 students, is a health sciences university that comprises Rush Medical College, the College of Nursing, the College of Health Sciences and the Graduate College. Numerous national organizations have recognized Rush for the quality of care we provide, including U.S. News & World Report, which ranked Rush University Medical Center among the top 50 hospitals in 7 of 16 specialties in its 2018-2019 Best Hospitals issue. Rush University Medical Center has received Vizient's Quality Leadership Award, ranking second among 99 academic medical centers across the country. In 2018, Rush was named a leader in LGBT health care equality by the Human Rights Campaign for the ninth consecutive year, and was one of only five hospitals from across the nation to be recognized by the American Hospital Association as an honoree for its annual Equity of Care Award.

Interested candidates, please address your CV and cover letter to:

**Timothy M. Kuzel, MD, FACP
The Samuel G. Taylor III, MD, Professor of Oncology
Chief, Division of Hematology, Oncology and Cell Therapy
Rush University Medical Center**

via email to **Rose Sprinkle, Manager, Faculty Recruitment at
Rose_Sprinkle@Rush.edu**

Rush is an equal opportunity / Affirmative Action employer



Memorial Sloan Kettering Cancer Center

Chief, Lymphoma Service
Division of Hematologic Malignancies
Department of Medicine

The Division of Hematologic Malignancies in the Department of Medicine at Memorial Sloan Kettering Cancer Center is seeking to recruit an exceptional academic physician and leader to serve as

Chief of the Lymphoma Service. The Division of Hematologic Malignancies is made up of 89 physicians in five services, including: Lymphoma, Leukemia, Myeloma, Benign Hematology and Adult Bone Marrow Transplantation. The Lymphoma Service is comprised of 21 physicians, involved in clinical care as well as clinical and laboratory-based research.

The new service chief will report to the Head, Division of Hematologic Malignancies, and will have programmatic oversight and responsibility for the service and faculty. The service chief will work to shape the strategic and programmatic priorities for the service, clinical excellence, clinical operational efficiency, talent acquisition and retention, research, grant funding, professional development, mentorship and teaching. The administrative infrastructure available in the service will allow the service chief to maintain both a clinical practice and an independent research program.

At a minimum, qualified candidates should be/should have a:

- Nationally recognized clinician as well as a leader in clinical, translational, laboratory based or population science
- Extensive knowledge of the clinical care of patients with lymphoid malignancies
- Board-eligible or board-certified in Medical Oncology
- The requirements for licensure in New York State

MSK has a strong commitment to enhancing the diversity of its faculty and staff. Applicants from diverse racial, ethnic, and cultural backgrounds are encouraged to apply. MSK offers competitive salaries and benefits.

Interested applicants should send curriculum vitae and letter of interest to **Sonia Román at romans1@mskcc.org**.

MSK is an equal opportunity and affirmative action employer committed to diversity and inclusion in all aspects of recruiting and employment. All qualified individuals are encouraged to apply and will receive consideration without regard to race, color, gender, gender identity or expression, sexual orientation, national origin, age, religion, creed, disability, veteran status or any other factor which cannot lawfully be used as a basis for an employment decision. Federal law requires employers to provide reasonable accommodation to qualified individuals with disabilities. Please tell us if you require a reasonable accommodation to apply for a job or to perform your job. Examples of reasonable accommodation include making a change to the application process or work procedures, providing documents in an alternate format, using a sign language interpreter, or using specialized equipment.



blood® Classifieds

**Professional
Opportunities**

<http://www.bloodjournal.org/>

For advertising information contact:

Eamon Wood

Pharmaceutical Media, Inc.

30 East 33rd St.

New York, NY 10016

Tel: (212) 904-0363

ewood@pminy.com



blood®